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Abstract: 
Alzheimer's disease (AD) an ailment that is supposed to affect people in old age. There are evidences that it might affect 
others also. The number of elders is increasing as the average life expectancy is increasing. AD afflicts its patients with the 
dementia and AD might increase in malignance over time. People with cognitive disabilities can be overwhelmed through 
cognitive prosthetics. With the help of information technology   we can enhance the quality of life. Significant achievements 
are possible with an interdisciplinary approach that includes genomic, genetic, technological and therapeutic measures. The 
combination and coordination of Bioinformatics facilitates generation of various diagnostic tools for the people who are 
suffering from Alzheimer's disease. These tools help the care providers also. In this article, we emphasize the literature 
regarding the use of technology and its methodologies to improve the quality of care for the people with Alzheimer's 
disease. 
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Background: 
Alzheimer's disease (AD) was first discovered in 1907 by 
German neurologist Alois Alzheimer. [1] Alzheimer's 
disease becomes one of the major hurdles for further 
survival of elders thereby a many number of people may 
suffer from AD in the next few decades. Molecular genetics 
reached human genetics about 1976, when the
 first human 
genes were cloned [2] Transgenic methods, ‘knock-outs’
 
and ‘knock-ins’ began in about 1986, and in about
 1996, 
database searching became a fruitful way to do genomic
 
research [3] The term ‘genome’ refers to an organism's
 
complete set of genes and chromosomes. The term 
genomics
  describes the scientific discipline of mapping, 
sequencing,
 and analyzing genomes. [4] 
 
The fact that most diseases do not follow a simple 
inheritance
 patterns has led to a significant challenge in the 
genetic dissection
  of the complex traits of diseases such 
hypertension, Alzheimer's
  disease, schizophrenia and 
diabetes. Alzheimer's (AD) afflicts its patients with a 
dementia that increases in malignance over time: the older 
an AD patient is, the worse the dementia is. Dementia is a 
result of the loss of neurons in the brain that assist in 
engagement of intellectual activities. The loss of neurons 
specifically affects the hippocampus, which is a central 
region for memory operation, and the cerebral cortex. The 
cerebral cortex is also involved in memory functions, but 
also works to accomplish reasoning and language 
functions. A big difference between a normal brain and a 
brain afflicted with AD is the presence of protein clusters 
inside and between neurons. The clusters inside are known 
as neurofibrillary tangles, which consist of a protein named 
tau. Another type of protein known as beta-amyloid is the 
protein that exists between neurons. While the presence of 
tau seems to be proportionate to the degree of dementia 
experienced by the patient, indicating a possible connection 
to the cause of AD, it is not unique to AD the way beta-
amyloid plaques are in their unique concentrations. These 
beta amyloid proteins that cluster between neurons are 
accompanied by the immune system's microglia, reactive 
inflammatory cells that are thought to remove already 
damaged neurons and/or the amyloid plaques themselves. 
[1] They originate from the beta-amyloid precursor protein 
(bAPP) when a bAPP fragment that is 99 amino acids is cut 
by gamma-secretase, creating a beta-amyloid peptide, while 
the amyloid plaques themselves are present in most old 
people, the high concentration of them in the hippocampus 
and cerebral cortex in AD patients suggests a role in the 
neuronal degenerative process. 
 
Memory loss is the most common and well known 
symptom for Alzheimer's disease. Other symptoms include 
loss of cognitive abilities, judgment, thinking and 
disorientation to place and time. Identification loss, 
depression, confusion, anxiety, fear, frustration, paranoia 
are also symptoms for Alzheimer's disease. The above 
symptoms may have different effects on different people. 
Currently medicines that are available for Alzheimer's 
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symptoms such as anxiety or sleeplessness. However, there 
is no available cure for Alzheimer's disease. While the 
curative approach is certainly crucial to combating the 
effects of AD, one avenue we might consider looking down 
is a focus on supplemental measures. 
 
The development of new technologies that could help AD 
patients cope with loss of mental function might be 
appropriate, given the nature of the ailment. Developments 
in information technology could be offer assistance to AD 
patients in way that could supplement the loss of biological 
function with mechanical functions. For example, a 
computer could be used to keep records of family members 
to help remind the patient about his or her past. While a 
desktop PC seems somewhat impractical for this, a 
computer small enough to fit into someone's eyeglasses, 
coupled with voice and image recognition technology, 
could provide AD patients with the kinds of information 
they need to continue to function. This, along with drugs to 
at least slow the process, could provide a treatment that 
could restore a quality of life to the patient in a way that is 
currently unavailable. 
 
A substantial number of the IMI patients reflected regional 
hypometabolism similar to AD, suggesting that IMI is 
likely an early stage in progressive dementia. A large 
percentage of IMI patients converted clinically to AD 
within three years of initial study, though they observed 
impaired memory functioning well before a clinical 
diagnosis of AD could be made. In addition to potential 
clinical utility, IMI and PET represent an opportunity to 
study dementia in relation to brain chemistry at a time 
when brain pathology is in the process of development. 
 
Genomics of alzheimer’s disease 
Genome analysis may be divided into structural and 
functional
 genomics. Structural genomics is an initial phase 
of genome
 analysis, and has a clear end point which is the 
construction
  of high-resolution genetic, physical, and 
transcript maps of
  an organism (its complete DNA 
sequence). This genotypic approach
  focuses on 
understanding how genotypic variation gives rise
  to 
phenotypic variation, relying on physical and genetic maps
 
and easily-typed DNA sequence polymorphisms. The 
expression
  approach (functional genomics) relies on the 
large collection
 of partially sequenced cDNA clones. The 
benefits of the information
 arising from the accumulation of 
human gene sequences includes
  developing systematic 
ways of finding genes of interest, and
 their functions; hence 
‘functional genomics’. The
  genes cloned and their 
corresponding DNA sequences provide the
  tools for 
comprehensive characterization of the expression patterns
 
of this entire set of genes, and for systematic experimental
 
investigations of the functional properties of their products.
 
Thus, functional genomics, which represents a new phase 
of genome
 analysis, makes use of the structural genomics 
information.
  The investigation is primarily a systematic 
approach to elucidate
 the genome and its functions.
  
 
Pathologically, Alzheimer's disease (AD) is associated with
 
generalized degeneration of the cerebral cortical and 
hippocampal
  neurons. Cholinergic neurons in the basal 
forebrain which project
 to cortex and hippocampus appear 
to be particularly vulnerable,
  and to an extent, so are 
serotonergic and noradrenergic afferents
 to cortical regions. 
The extracellular deposition of peptide
 fragments (amyloid-
beta) from the larger membrane precursor
 protein (APP) is 
typical in affected brain tissue. Intracellular
 accumulations 
of tau-proteins (tangles) are present in many
 cortical and 
cortico-limbic regions. [5]
 
 
Genetic studies have led to the identification of three genes
 
in which mutations can cause AD: the β-amyloid precursor
 
protein gene located on chromosome 21, presenilin 1 (PS1) 
located
 on chromosome 14 and presenilin 2 (PS2) located 
on chromosome
 1. [6, 7, 8] In addition, the E4 allele of the 
apolipoprotein
 E (ApoE) gene is a risk factor for AD. While 
mutations associated
 with APP are extremely rare, the 50 or 
so mutations associated
 with PS1 may explain up to half of 
all cases of early-onset
 AD. A study which investigated the 
association of two candidate
  genes (PS1 and α1-
antichymotrypsin (ACT)) with the risk of sporadic
 
Alzheimer's disease on chromosome 14 reported that the 
frequency
 of the ACT*A allele was significantly higher in 
AD patients
 than in controls and the stratification of the 
ACT data by PS1
 genotypes showed that the risk associated 
with the ACT*A allele
  was confined to PS1*1 carriers 
only. [9] 
 
The two-site haplotype
 data for PS1 and ACT indicated that 
the A1 haplotype, carrying
 the ACT*A and PS1 alleles, was 
more frequent in Alzheimer's
  disease patients, and these 
results may also suggest that there
 is a possible synergistic 
effect of these two loci on the risk
 of AD. In contrast to 
early-onset AD, there is to date only
  one genetic factor 
indisputably linked with late-onset forms
 of this disorder; 
the E4 allele of apolipoprotein E. [10] Differences
 in ApoE 
genotyping appear to explain differences in patients'
 
responses to drug therapy. With tacrine, a better response 
was
 seen in patients with the ApoE E2 or ApoE E3 allele 
than in
 those carrying the ApoE E4. The ApoE E4 allele 
has an inverse
  relationship with residual brain choline 
acetyltransferase (the
 acetyl-choline synthesizing enzyme) 
activity, and it appears
 that patients with this genotype may 
not have sufficient acetylcholine
  to benefit from a drug 
which acts as an inhibitor of acetylcholinesterase.
 However, 
patients with the ApoE E4 genotype appear to have a
 better 
response than other AD patients to treatment with another
 
drug, Servier's S12024 (morpholinyl-2 methoxyl-8 
tetrahydro-1, 2, 3, 4
 quinoline) which is currently in phase 
II clinical trials. In
 fact, this drug had no detectable effect in 
patients with the
 other ApoE genotypes. S12024 does not 
appear to affect the cholinergic
  system, but rather to 
facilitate brain noradrenergic and vasopressinergic
 activity, 
and increases vasopressin synthesis and release in
 a dose-
dependent manner. There may be a balance between 
cholinomimetic
 and vasopressinergic pathways, according 
to ApoE E4 allele presence
 or absence. [11] With relevance Bioinformation by Biomedical Informatics Publishing Group                   open access 
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to design of clinical trials,
 the important observation may 
be that alleles that appear to
 be conclusively associated with 
a therapeutically relevant phenotype
 can be used to select a 
subgroup of patients for clinical trials.
  
 
A polymorphic site need not be part of the target for the 
drug;
 it only needs to be associated with a response to the 
treatment.
  In responsive patients, the selective treatment 
could be more
 effective, and associated with fewer or less 
severe side effects.
  Furthermore, pre-emptive genotyping 
aimed at drug-associated
 genes could mean that fewer drug 
candidates would fail to reach
 the market place because of 
poor toxicity/efficacy profiles
 in the general population. For 
example, genotyping of early-onset
 AD is likely to include 
the two PS1 and PS2 genes involved in
  this disease. 
Predictive and diagnostic tests for PS1 mutations
  and 
diagnostic tests for ApoE alleles are already commercially
 
available and other tests are being developed. Thus, genetic
 
testing for AD exists for clinical use, and is likely to be
 
used more often to stratify patients in Alzheimer's disease
 
research, both in trials of preventive products and in tests
 of 
new pharmacological treatments. Therefore, predictive and
 
diagnostic genetic testing for these highly penetrant 
mutations
 such as PS1 or PS2 may be appropriate for adults 
from families
 with a clear autosomal dominant pattern or 
inheritance, particularly
 those with a family history of early 
onset of symptoms. Testing
  is an option that could be 
discussed and that could reasonably
 be accepted or declined 
by the patients. However, the application
 of the ApoE test 
raises concerns, because although the E4 allele
 is associated 
with an increased risk of AD, its predictive value
  for 
individuals is quite limited. [11] The small increase in 
diagnostic
 confidence provided by ApoE genotyping does 
not justify the
 burdens of testing; such testing may have 
value in AD research,
  but its widespread clinical use is 
premature until practical
 benefits outweigh its costs.
  
 
Information technology-Alzheimer’s disease 
Information technology role on Alzheimer's disease has 
already begun. In 2003, Intel entered in to a consortium 
with the Alzheimer's association, granting $1 million in 
Information technology research to be directed towards AD 
patients. Technology such as sensor networks is being used 
to study the habits of Alzheimer's disease patient behavior 
in hopes of finding ways to learn more about AD and to 
make it more livable. This is an example of how 
Information technology can work for AD patients. Scientist 
Hans Moravec has suggested that someday, entire human 
brains and the consciousnesses they hold will be able to be 
downloaded into a computer. This would certainly avoid 
the problem of neuronal deterioration, but it's possible that 
by the time, we have the technology to move minds into 
machines, we will know enough about AD to make it a 
livable or curable illness. 
 
The early stage of AD primarily causes memory problems. 
At this stage a person can live independently and only 
requires assistance in remembering certain tasks. Cognitive 
prosthetics are helpful in aiding a person to remember such 
tasks. A pager was used to help a person remember the 
tasks during the early stage of AD. The Pager was able to 
record 80 letter alphanumeric message and then display the 
message at scheduled time. The person was able to perform 
the tasks independently within a week by using the pager. 
The functional memory of the person had improved after 
using the pager for six months. 
 
The majority of people with AD usually fit into the 
category of mild to moderate disease progression. At this 
stage it is common for patients with AD to move-in with a 
caregiver. During these stages, persons with AD are prone 
to forgetting their way home or wandering in the streets. 
The use of technology for people with AD provides hope 
that they can live on their own for longer period. Global 
Positioning System (GPS) is the technology that may prove 
to be very helpful in these stages. GPS is a tracking device 
that can be used to identify the location of the patients. A 
patient can wear a GPS unit and a caregiver can be notified 
when the patient wanders out of the designated area. 
Currently GPS devices used to locate Alzheimer’s patients 
are being used with personal locater devices. 
 
During the moderate to late stages of AD, behavioral 
disturbances need for more care. At this stage, motes can be 
programmed to inform caregiver of all the conditions of the 
patient. Sensors could be placed in the person's bed to 
monitor weight loss. A combination of sensors placed in 
chairs and infrared tags detected by cameras could inform 
the caregiver, if the AD patient has fallen down or is sitting 
in the chair. 
 
Information technology can be used to help the caregivers 
with the responsibilities of monitoring the AD patients as 
well as informing the caregivers about AD and answering 
their questions. For example, a telephone-based 
intervention has been used to provide help and support to 
caregivers. The Project is known as REACH (Resource for 
Enhancing Caregiver Health) used an interactive voice 
response (IVR) to provide support and answers to 
caregivers. It is necessary for the caregiver to receive the 
support they need in order to perform their job easily. The 
World Wide Web can easily solve the problem by 
providing knowledge and support to the caregivers. They 
can get the validity of online information from the online 
service called Alzonline.net. [12]  
 
Healthcare providers and caregivers are responsible for 
constantly monitoring the patient's condition. It is not 
possible for many caregivers to constantly monitor the 
patient's health because of lack of medical knowledge or 
equipment. [13] An important part of care giving consists 
of taking the patients to the physician, this can add further 
stress to the care giver and affect the accuracy of 
physician's judgment about the patient's condition. A 
healthcare provider might have a better idea regarding a 
patient’s condition if they could monitor the patient in a 
natural setting. A telehealth system could be used in order Bioinformation by Biomedical Informatics Publishing Group                   open access 
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for the healthcare provider to monitor the patients in their 
home setting. 
 
Telehealth technology can be useful for rural caregivers. 
They need not drive long distances. Telehealth application 
can be used to monitor patients at home and eliminate 
unnecessary travel. A number of telehealth applications 
have been used to monitor the patients. Information 
technology can play a very important role to improve the 
condition of the people with Alzheimer's disease. It can 
provide a caregiver with information and support. On the 
other hand it can engage the patients in many different 
activities to reduce the caregivers stress. A combination of 
telemedicine, telecommunication projects and technologies 
for daily living can help us with the aging of our elders the 
medical conditions they will face. 
 
Electronic medical records 
The main purpose of clinical care and research is to discern 
patterns and modify treatment according to changing 
parameters, be they weight, blood pressure, plasma glucose 
or serum lipids. Records on paper can be scanned and 
browsed easily but the data may not be recorded in a 
uniform fashion, papers may be lost, misplaced or become 
complex .The relevant paper records cannot easily be 
sorted and they cannot be accessed across different 
locations. [14] Electronic medical records have advantages 
over paper records, vz: complete and comprehensive 
flexibility in storage and retrieval of data, which can be 
used for publication, presentation and research. 
Computerized guidelines can provide evidence-based 
recommendations by allowing access to references, 
showing errors and sending reminders. [15] Besides, 
interactive telemedicine support is possible. Information 
laws of the country can be expected to consider EMR as a 
legal document. They may be electronically signed and 
must be permanent. An identifier must be attached to any 
further modifications. 
 
Bioinformatics-Biological databases 
Bioinformatics is the science of using and developing 
computational tools and algorithms to help in solve 
different biological problems. These problems include 
similarity searches of unknown DNA/protein sequences 
and the prediction of protein structure and function. 
Bioinformatics can be useful in finding the causative genes 
for Alzheimer's disease. The genome information can be 
obtained from existing biological databanks to analyze their 
structure and function. Therefore Biological databases 
plays important role in bioinformatics. There are around 
500 public and commercial biological databases. These 
databases usually contain genomics and proteomics data, 
but databases are also used in taxonomy. The data are 
nucleotide sequences of genes or amino acid sequences of 
proteins. Furthermore information about function, structure, 
localization on chromosome, clinical effects of mutations 
as well as similarities of biological sequences can be found. 
 
Biological databases have become an important tool in 
assisting scientists to understand and explain a host of 
biological phenomena from the structure of biomolecules 
and their interaction, to the whole metabolism of organisms 
and to understanding the evolution of species. This 
knowledge helps facilitate the fight against diseases, assists 
in the development of medications and in discovering basic 
relationships amongst species in the history of life. The 
biological knowledge of databases is usually (locally) 
distributed amongst many different specialized databases. 
This makes it difficult to ensure the consistency of 
information, which sometimes leads to low data quality. 
We can extract the genes that are causing AD from gene 
cards using bioinformatics. 
 
Computer applications for clinical questions 
Although prospective learning will always be important for 
health care professionals, it is not possible to prospectively 
obtain all of the knowledge required to appropriately treat 
all patients. Therefore, clinicians must be able to access 
knowledge at the point of care that answers clinical 
questions and provides diagnostic and therapeutic decision 
support. A number of available computer applications 
address this need. Three of these are highlighted here. 
Many Internet sites can provide valuable information to 
clinicians, and the applications can be accessed on the 
Internet using the websites like www.UpToDate.com, 
www.infopoems.com, etc. 
 
Conclusion: 
Information technology plays a vital role in identification 
of the genes that are causing AD, disease management, 
progression and online data collection using electronic 
medical records for future research. The use of technology 
has the potential to help the patients to be more 
independent and reduce stress on the caregiver. The use of 
Information technology is might be worth pursuing if 
technology advances faster than a treatment or cure. 
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